How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...

CEO Chris Gibson highlighted significant progress in 2024, including clinical data readouts from REC-617 and REC-994, which showed early efficacy signals and robust safety, respectively. REC-617, a ...

This price reflects trading activity during the overnight session on the Blue Ocean ATS, available 8 PM to 4 AM ET, Sunday through Thursday, when regular markets are closed.

Entering text into the input field will update the search result below Entering text into the input field will update the search result below ...